Current Report Filing (8-k)
29 Giugno 2023 - 3:01PM
Edgar (US Regulatory)
0001557376
false
0001557376
2023-06-29
2023-06-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): June 29, 2023
ORGANICELL REGENERATIVE MEDICINE, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-55008 |
|
47-4180540 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
3321 College Avenue, Suite 246
Davie,
Florida |
|
33314 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (888) 963-7881
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As
used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the
Company,” “Organicell,” “we,” “us” and “our” refer
to Organicell Regenerative Medicine, Inc. and its subsidiaries.
Item 7.01 |
Regulation
FD Disclosure. |
On
June 29, 2023, Organicell issued a press release regarding the appointment of Howard L. Golub, M.D., as its Executive Vice President
and Chief Science Officer. A copy of the press release is attached as Exhibit 99.1 to this Report.
The
foregoing information, including the press release attached as Exhibit 99.1 to this Report, is being furnished pursuant to Item 7.01
of this Current Report and shall not be deemed “filed” for the purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.
Item 9.01 |
Financial
Statements and Exhibits. |
* |
Furnished
but not filed. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
June 29, 2023 |
ORGANICELL
REGENERATIVE MEDICINE, INC. |
|
|
|
|
By: |
/s/
Ian Bothwell |
|
Ian
Bothwell |
|
Chief
Financial Officer |
Grafico Azioni Organicell Regenerative ... (QB) (USOTC:OCEL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Organicell Regenerative ... (QB) (USOTC:OCEL)
Storico
Da Lug 2023 a Lug 2024